Effects of sulfasalazine on lipid peroxidation and histologic liver damage in a rat model of obstructive jaundice and obstructive jaundice with lipopolysaccharide-induced sepsis. 2009

Musa Dirlik, and Aydin Karahan, and Hakan Canbaz, and Mehmet Caglikulekci, and Ayşe Polat, and Lulufer Tamer, and Suha Aydin
Department of General Surgery, Mersin University Medical School, Mersin, Turkey.

BACKGROUND Sulfasalazine, an inhibitor of cyclooxygenase, 5-lipoxygenase, and nuclear factor κB (NF-κB), has been found to alleviate oxidative damage, proinflammatory cytokine production, bile-duct proliferation, neutrophil infiltration, and fibrosis. Therefore, it may have a potential effect in attenuating lipid peroxidation and histologic liver damage in patients with biliary obstruction and biliary obstruction with sepsis. OBJECTIVE The aim of this study was to investigate the effect of sulfasalazine on lipid peroxidation and histologic liver damage due to obstructive jaundice (OJ) and to OJ with lipopolysaccharide (LPS)-induced sepsis in an experimental model. METHODS Male Wistar rats, weighing 150 to 220 g, were randomized into 6 groups: OJ; OJ + LPS; OJ + sulfasalazine; OJ + sulfasalazine + LPS (sulfasalazine administered before sepsis); OJ + LPS + sulfasalazine (sulfasalazine administered after sepsis); and sham. Liver malondialdehyde (MDA) and myeloperoxidase (MPO) activities were assessed to monitor lipid peroxidation and neutrophil infiltration in liver tissue. Histologic liver damage was evaluated with hematoxylin-eosin stained slides. Liver tissue NF-κB and caspase-3 expression were studied immunohistopathologically to evaluate lipid peroxidation, liver damage, and hepatocyte apoptosis. RESULTS Forty-eight rats were evenly randomized into 6 groups of 8. MDA (P = 0.001), MPO (P = 0.001), NF-κB (P = 0.003), caspase-3 expression (P = 0.002), and liver injury scores (P = 0.002) increased significantly in the OJ group compared with the sham group. Compared with the OJ group, MDA (P = 0.030) and MPO levels (P = 0.001), and liver injury scores (P = 0.033) were decreased significantly in the OJ + sulfasalazine group. In the OJ + sulfasalazine + LPS and OJ + LPS + sulfasalazine groups, MDA (P = 0.008 and P = 0.023, respectively) and MPO (both, P = 0.001) were significantly decreased; however, liver NF-κB, caspase-3 expression, and liver injury scores were not significantly different compared with the OJ + LPS group. There was no significant difference between the OJ + LPS + sulfasalazine and OJ + sulfasalazine + LPS groups in regard to all end points when comparing the effects of sulfasalazine administered before or after sepsis. CONCLUSIONS Sulfasalazine was associated with decreased neutrophil accumulation and lipid peroxidation in these rats with OJ. Administration of sulfasalazine before or after LPS-induced sepsis was associated with a reduction in lipid peroxidation and neutrophil accumulation; however, it did not attenuate histologic liver damage. There was no difference between the findings when sulfasalazine was administered before or after sepsis in OJ.

UI MeSH Term Description Entries

Related Publications

Musa Dirlik, and Aydin Karahan, and Hakan Canbaz, and Mehmet Caglikulekci, and Ayşe Polat, and Lulufer Tamer, and Suha Aydin
January 2006, Journal of investigative surgery : the official journal of the Academy of Surgical Research,
Musa Dirlik, and Aydin Karahan, and Hakan Canbaz, and Mehmet Caglikulekci, and Ayşe Polat, and Lulufer Tamer, and Suha Aydin
September 1990, Journal of ethnopharmacology,
Musa Dirlik, and Aydin Karahan, and Hakan Canbaz, and Mehmet Caglikulekci, and Ayşe Polat, and Lulufer Tamer, and Suha Aydin
June 2012, Peptides,
Musa Dirlik, and Aydin Karahan, and Hakan Canbaz, and Mehmet Caglikulekci, and Ayşe Polat, and Lulufer Tamer, and Suha Aydin
March 2015, Naunyn-Schmiedeberg's archives of pharmacology,
Musa Dirlik, and Aydin Karahan, and Hakan Canbaz, and Mehmet Caglikulekci, and Ayşe Polat, and Lulufer Tamer, and Suha Aydin
June 1991, Cancer letters,
Musa Dirlik, and Aydin Karahan, and Hakan Canbaz, and Mehmet Caglikulekci, and Ayşe Polat, and Lulufer Tamer, and Suha Aydin
May 2004, Current therapeutic research, clinical and experimental,
Musa Dirlik, and Aydin Karahan, and Hakan Canbaz, and Mehmet Caglikulekci, and Ayşe Polat, and Lulufer Tamer, and Suha Aydin
May 2022, Drug and chemical toxicology,
Musa Dirlik, and Aydin Karahan, and Hakan Canbaz, and Mehmet Caglikulekci, and Ayşe Polat, and Lulufer Tamer, and Suha Aydin
September 1988, Lipids,
Musa Dirlik, and Aydin Karahan, and Hakan Canbaz, and Mehmet Caglikulekci, and Ayşe Polat, and Lulufer Tamer, and Suha Aydin
January 1989, Farmakologiia i toksikologiia,
Musa Dirlik, and Aydin Karahan, and Hakan Canbaz, and Mehmet Caglikulekci, and Ayşe Polat, and Lulufer Tamer, and Suha Aydin
January 1991, Free radical biology & medicine,
Copied contents to your clipboard!